Peritoneal Ultrafiltration in Cardio Renal Syndrome.

NCT ID: NCT03994874

Last Updated: 2025-05-16

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 84 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-16
• Study Completion Date: 2027-06-30

Brief Summary

Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).

Detailed Description

The study will include adults HFrEF patients, that despite guidelines directed medical therapy still retain a congestive heart failure (HF) picture. During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change. Patients will be assigned randomly to receive either PolyCore PUF (over the top of their prescribed heart failure medications), for 6 months, or to the control arm receiving stable medical therapy according to international guidelines and comprehensive of loop diuretic (furosemide) dose till to 2.5mg/kg/day, without PUF therapy. The PUF ultrafiltration will be performed with a single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours, for 6 months. An independent data safety monitoring board (DSMB) will be convened for this study and will review the results of the trial at regular intervals to protect patients participating in the study. An adaptive interim analysis will be performed when in each group 20 patients have completed 6 months in the study, for analysis of the primary outcome. The purpose of the adaptive interim analysis is to calculate the final study sample size.The DSMB will closely examine the interim primary efficacy results, respecting the confidentiality and integrity of data, to investigate the final sample sizes necessary to complete the study.

Conditions

Congestive Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

PolyCore PUF

PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.

Group Type: EXPERIMENTAL

PolyCore (Polydextrin, L-Carnitine, D-xylitol)

Intervention Type: DRUG

A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.

Control

Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

PolyCore (Polydextrin, L-Carnitine, D-xylitol)

A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.

Intervention Type: DRUG

Other Intervention Names

PolyCore peritoneal dialysis solution

Eligibility Criteria

Inclusion Criteria

• Age ≥18 yrs
• Left ventricular ejection fraction ≤60%
• NYHA Classification of III-IV despite guidelines directed medical therapy
• Right ventricular failure due to after load mismatch, addressed by the presence of tricuspid calve regurgitation (≥ moderate) and by the disproportioned increase of the right atrial pressure (RAP) versus the capillary wedge pressure (CWP) with a ratio ≥0.65, detected with right heart catheterization performed after stable medical therapy according to international guidelines and comprehensive of loop diuretic (equivalent to furosemide oral dose till 2.0 mg/kg/day), coupled with urinary sodium excretion ≤ mEq/L, confirmatory of loop diuretic resistance.
• Cava vein enlargement (inner diameter, detected with focused echocardiography, between 1,5 and 2,5 cm, with respiratory collapse <50% or absent due to intravascular fluid overload)
• Decreased kidney function addressed by the measurement of glomerular filtration rate (GFR) urea clearance + creatinine clearance/2 (>15 ml/min/1,73 m2)
• NT pro-BNP plasma concentration > 1000 pg/ml or BNP plasma concentration > 250 pg/ml
• at least one episode of pulmonary or systemic congestion requiring high-dose intravenous diuretics (or diuretic combinations) in the 6 months befor the study enrollment
• An appropriate PUF technique candidate.
• Signed informed consent

Exclusion Criteria

• Recipients of heart transplantation
• Presence of a mechanical circulatory support device;
• Hypertrophic obstructive cardiomyopathy;
• Uncontrolled hypertension with systolic blood pressure ≥ 160 mmHg
• Severe valvular stenosis;
• Restrictive cardiomyopathy;
• Acute coronary syndrome ≤ 6 months before;
• Active myocarditis
• Cardiosurgical or Endo-radiological heart procedures ≤ 6 months before
• Cardiac resynchronization therapy (CRT) implantation or upgrading of pacemaker (PM) or implantable cardioverter defibrillator (ICD) to CRT ≤ 6 months before;
• Patient with end-stage renal disease, GFR urea clearance + creatinine clearance/2 (<15 ml/min/1,73 m2 GFR)
• Any major organ transplant (liver, lung, kidney)
• Lung embolism ≤ 6 months before;
• Fibrotic lung disease;
• Liver Cirrhosis;
• Absolute contraindication to peritoneal catheter implantation;
• Logistical and or organizational contra-indication to treatment
• Active malignancy;
• Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical trial and for three months later
• Female patients of childbearing age who do not use adequate contracteption.
• Unwilling and unable to give informed consent;
• Enrolment in another clinical trial involving medical or device based interventions.
• Hypersensibility to IMP components.
• Evidence of any condition that, according to the investigators' judgment, could expose the subject to undue risk and/or prevent the subject from participating in the study procedures and/or potentially afftecting the study quality data.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Iperboreal Pharma Srl

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Edoardo Gronda, MD

Role: STUDY_DIRECTOR

Policlinico Milano - on behalf of Cardio Renal and Metabolism Working Group of the ANMCO

Locations

Ospedale Ss. Annunziata

Chieti, , Italy

Site Status: RECRUITING

ASST FBF Sacco

Milan, , Italy

Site Status: RECRUITING

Ospedale Monaldi

Napoli, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Arduino Arduini, MD

Role: CONTACT

a.arduini@corequest.ch

+41 79 7878312

Facility Contacts

Mario Bonomini, MD

Role: primary

Maurizio Gallieni, MD

Role: primary

Giuseppe Pacileo, MD

Role: primary

Other Identifiers

CQ012019

Identifier Type: -

Identifier Source: org_study_id